10-Q quarterly report · filed Nov 4, 2026

McKesson Corporation (MCK) Q3 2026 10-Q Quarterly Report

Short answer

McKesson Corporation (MCK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $111.0B (up 7.6% year over year) with net income of $1.2B.

Q3 2026 key financials · XBRL

Revenue
$111.0B
+7.6% YoY · +5.3% QoQ
Net income
$1.2B
+9.7% YoY · +98.4% QoQ
Operating margin
1.4%
Gross margin
3.6%
EPS (diluted)
$10.38
+16.5% YoY · +101.6% QoQ

Source: XBRL data from the McKesson Corporation (MCK) Q3 2026 10-Q on SEC EDGAR. USD.

McKesson Corporation Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $110,957M, up 8% YoY from $103,150M, driven by pharmaceutical volumes and specialty pharmaceuticals
  • Gross margin 3.57% vs 3.43% YoY, operating-expense ratio 2.12% vs 2.07%
  • Best segment Oncology & Multispecialty: revenue $14,980M, up 24%; worst margin trend Medical-Surgical Solutions: 5.30% vs 7.47%
  • Operating cash flow $2,850M vs $1,502M; cash balance $6,619M vs $4,068M at March 31
  • Capital deployment: $3,400M repurchases and $198M dividends; regulatory uncertainty, drug pricing, and opioid liabilities remained headwinds

Risk Factors

  • No material changes to 10-K risk factors during the quarter
  • Carried-forward risks remain unchanged, including regulatory, legal, operational, competitive, market, liquidity, debt, currency and concentration exposures

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other McKesson Corporation quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.